Growth factors for therapeutic angiogenesis in peripheral arterial disease
- PMID: 17762548
- DOI: 10.1097/HCO.0b013e328236741b
Growth factors for therapeutic angiogenesis in peripheral arterial disease
Abstract
Purpose of review: Peripheral arterial disease is a common disease that has few treatment options. Angiogenesis is defined as the growth of new blood vessels from preexisting vasculature. Therapeutic angiogenesis is an investigational method that uses vascular growth to alleviate disorders of tissue ischemia, such as coronary artery disease and peripheral arterial disease. There have been tremendous changes in the field of therapeutic angiogenesis over the past decade, and there is much promise for the future.
Recent findings: Initial preclinical work with cytokine growth factor delivery resulted in a great deal of enthusiasm, but larger clinical studies have failed to achieve similar success. With an increased understanding of the complex mechanisms involved in angiogenesis, gene therapy and cell therapy have moved to the forefront of therapeutic angiogenesis. Novel therapies which target multiple different angiogenic pathways are also being developed and tested.
Summary: Therapeutic angiogenesis is an exciting field that continues to evolve. This review will focus on the different growth factors being used, their routes of delivery, the results of clinical trials, and some of the novel therapies being developed.
Similar articles
-
Growth factors for therapeutic angiogenesis in hypercholesterolemic erectile dysfunction.Asian J Androl. 2008 Jan;10(1):23-7. doi: 10.1111/j.1745-7262.2008.00372.x. Asian J Androl. 2008. PMID: 18087640 Review.
-
Growth factor-induced therapeutic neovascularization for ischaemic vascular disease: time for a re-evaluation?Curr Opin Cardiol. 2006 Jul;21(4):376-84. doi: 10.1097/01.hco.0000231409.69307.d2. Curr Opin Cardiol. 2006. PMID: 16755208 Review.
-
Therapeutic angiogenesis for myocardial ischemia.Expert Rev Cardiovasc Ther. 2004 Mar;2(2):271-83. doi: 10.1586/14779072.2.2.271. Expert Rev Cardiovasc Ther. 2004. PMID: 15151475 Review.
-
Therapeutic angiogenesis: a new treatment approach for ischemic heart disease--part I.Cardiol Rev. 2008 Jul-Aug;16(4):163-71. doi: 10.1097/CRD.0b013e3181620e3b. Cardiol Rev. 2008. PMID: 18562806 Review.
-
Gene therapy for ischemic cardiovascular diseases: some lessons learned from the first clinical trials.Trends Cardiovasc Med. 2004 Nov;14(8):295-300. doi: 10.1016/j.tcm.2004.09.001. Trends Cardiovasc Med. 2004. PMID: 15596105 Review.
Cited by
-
Dual pH- and temperature-responsive microparticles for protein delivery to ischemic tissues.Acta Biomater. 2013 May;9(5):6526-34. doi: 10.1016/j.actbio.2013.01.041. Epub 2013 Feb 9. Acta Biomater. 2013. PMID: 23402764 Free PMC article.
-
Intermittent claudication: new targets for drug development.Drugs. 2013 Jul;73(10):999-1014. doi: 10.1007/s40265-013-0078-3. Drugs. 2013. PMID: 23775528 Review.
-
Angiogenesis-related proteins as biomarkers for peripheral artery disease.Heliyon. 2023 Sep 15;9(9):e20166. doi: 10.1016/j.heliyon.2023.e20166. eCollection 2023 Sep. Heliyon. 2023. PMID: 37809892 Free PMC article.
-
Adeno-associated virus serotype 9 efficiently targets ischemic skeletal muscle following systemic delivery.Gene Ther. 2013 Sep;20(9):930-8. doi: 10.1038/gt.2013.16. Epub 2013 Mar 28. Gene Ther. 2013. PMID: 23535898 Free PMC article.
-
Use of alternative methodologies for evaluation of composite end points in trials of therapies for critical limb ischemia.Am Heart J. 2012 Sep;164(3):277-84. doi: 10.1016/j.ahj.2012.07.002. Am Heart J. 2012. PMID: 22980292 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous